Charles Schwab’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$334M Buy
3,693,034
+135,946
+4% +$11.4M 0.04% 327
2026
Q1
$285M Buy
3,557,088
+109,048
+3% +$8.99M 0.04% 320
2025
Q4
$294M Sell
3,448,040
-5,048
-0.1% -$414K 0.05% 322
2025
Q3
$269M Sell
3,453,088
-583,749
-14% -$45.6M 0.04% 335
2025
Q2
$316M Buy
4,036,837
+89,027
+2% +$6.64M 0.05% 283
2025
Q1
$286M Buy
3,947,810
+185,049
+5% +$13.2M 0.05% 287
2024
Q4
$279M Buy
3,762,761
+103,659
+3% +$7.26M 0.05% 291
2024
Q3
$241M Buy
3,659,102
+53,181
+1% +$3.86M 0.05% 323
2024
Q2
$333M Buy
3,605,921
+31,349
+0.9% +$2.78M 0.06% 258
2024
Q1
$342M Buy
3,574,572
+125,718
+4% +$10.6M 0.08% 225
2023
Q4
$263M Buy
3,448,854
+5,669
+0.2% +$394K 0.07% 261
2023
Q3
$239M Buy
3,443,185
+104,382
+3% +$8.39M 0.07% 252
2023
Q2
$315M Buy
3,338,803
+6,467
+0.2% +$562K 0.09% 197
2023
Q1
$276M Buy
3,332,336
+62,350
+2% +$4.9M 0.08% 208
2022
Q4
$244M Buy
3,269,986
+122,607
+4% +$9.45M 0.08% 230
2022
Q3
$260M Sell
3,147,379
-9,269
-0.3% -$892K 0.09% 195
2022
Q2
$300M Buy
3,156,648
+51,520
+2% +$5.33M 0.1% 181
2022
Q1
$366M Buy
3,105,128
+80,881
+3% +$9.07M 0.11% 166
2021
Q4
$392M Buy
3,024,247
+85,550
+3% +$9.98M 0.12% 159
2021
Q3
$333M Buy
2,938,697
+59,772
+2% +$6.82M 0.11% 164
2021
Q2
$298M Buy
2,878,925
+18,383
+0.6% +$1.73M 0.1% 181
2021
Q1
$239M Sell
2,860,542
-259,457
-8% -$21.9M 0.09% 199
2020
Q4
$285M Sell
3,119,999
-239,279
-7% -$19.8M 0.11% 167
2020
Q3
$268M Sell
3,359,278
-64,985
-2% -$5.07M 0.12% 150
2020
Q2
$237M Buy
3,424,263
+170,523
+5% +$12.1M 0.12% 167
2020
Q1
$205M Buy
3,253,740
+64,089
+2% +$4.62M 0.12% 159
2019
Q4
$248M Buy
3,189,651
+239,235
+8% +$18.7M 0.13% 142
2019
Q3
$216M Buy
2,950,416
+64,569
+2% +$4.54M 0.13% 151
2019
Q2
$178M Sell
2,885,847
-67,410
-2% -$4.08M 0.11% 178
2019
Q1
$188M Buy
2,953,257
+452,181
+18% +$25.8M 0.12% 154
2018
Q4
$128M Buy
2,501,076
+62,175
+3% +$3.15M 0.1% 186
2018
Q3
$142M Buy
2,438,901
+54,900
+2% +$2.69M 0.09% 189
2018
Q2
$116M Buy
2,384,001
+79,038
+3% +$3.69M 0.08% 219
2018
Q1
$107M Buy
2,304,963
+133,467
+6% +$5.8M 0.08% 230
2017
Q4
$81.6M Buy
2,171,496
+86,463
+4% +$3.17M 0.06% 285
2017
Q3
$76M Buy
2,085,033
+109,269
+6% +$4.17M 0.07% 285
2017
Q2
$77.9M Buy
1,975,764
+58,470
+3% +$2.13M 0.07% 269
2017
Q1
$60.1M Buy
1,917,294
+102,276
+6% +$3.2M 0.06% 310
2016
Q4
$56.7M Sell
1,815,018
-108,924
-6% -$3.53M 0.06% 304
2016
Q3
$77.3M Buy
1,923,942
+132,012
+7% +$4.97M 0.09% 223
2016
Q2
$59.6M Sell
1,791,930
-35,055
-2% -$1.2M 0.07% 270
2016
Q1
$53.7M Buy
1,826,985
+24,597
+1% +$679K 0.07% 285
2015
Q4
$47.5M Buy
1,802,388
+85,176
+5% +$2.21M 0.06% 295
2015
Q3
$40.7M Sell
1,717,212
-275,658
-14% -$6.65M 0.06% 306
2015
Q2
$47.3M Sell
1,992,870
-375,564
-16% -$8.48M 0.07% 288
2015
Q1
$56.2M Sell
2,368,434
-99,048
-4% -$2.22M 0.08% 251
2014
Q4
$52.4M Buy
2,467,482
+150,384
+6% +$3.02M 0.08% 248
2014
Q3
$39.4M Buy
2,317,098
+841,416
+57% +$13.3M 0.06% 283
2014
Q2
$21.1M Buy
1,475,682
+32,874
+2% +$446K 0.04% 471
2014
Q1
$17.8M Buy
1,442,808
+20,334
+1% +$235K 0.03% 505
2013
Q4
$15.6M Buy
1,422,474
+55,434
+4% +$625K 0.03% 513
2013
Q3
$16.2M Buy
1,367,040
+38,610
+3% +$452K 0.03% 462
2013
Q2
$14.8M Buy
+1,328,430
New +$15.7M 0.03% 459

Other funds holding EW

Charles Schwab's EW Position: Q2 2026 in Review

Charles Schwab increased its Edwards Lifesciences (EW) stake by 3.8% in Q2 2026, buying an estimated $11.4M and bringing the position to 3,693,034 shares worth $334M. The position accounts for 0.04% of the portfolio, ranked #327.

Charles Schwab first reported a position in EW in Q2 2013 and has held it in 53 quarters since. The position peaked at $392M in Q4 2021. 1,328 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Charles Schwab held 3,693,034 shares of Edwards Lifesciences worth $334M as of Q2 2026.
  • Charles Schwab bought 135,946 Edwards Lifesciences shares in Q2 2026, an estimated $11.4M.
  • Edwards Lifesciences made up 0.04% of Charles Schwab's portfolio in Q2 2026, its #327 holding.
  • Charles Schwab first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 53 quarters since.
  • Charles Schwab's Edwards Lifesciences position peaked at $392M in Q4 2021.
  • 1,328 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.